2020 “Yinhua Fund Cup” Sina bank financial planner competition, hot registration. From now on to September 7, you will receive free gift packages worth more than 700 yuan from Guan Qingyou, Luo Yuanshang, Chen Kaifeng and Jian Qi. According to the semi annual report disclosed by Zejing pharmaceutical this week (688266. SH), the net profit attributable to shareholders of listed companies was – 129 million yuan, and the net profit attributable to shareholders of listed companies after deducting non recurring profit and loss was – 144 million yuan. Zejing pharmaceutical is an innovation driven new chemical and biological drug R & D and production enterprise focusing on cancer, bleeding and blood diseases, hepatobiliary diseases and immune inflammatory diseases. < / P > < p > it is disclosed in the semi annual report that the company has independently developed a series of patent protected small molecule new drugs and double / triple specific antibody product pipelines, covering liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal carcinoma, bone marrow proliferative diseases and other malignant tumors, as well as bleeding, hepatobiliary diseases, autoimmune diseases and other treatment fields. As of the first half of the year, Zejing pharmaceutical and its wholly-owned subsidiary Shanghai Zejing have applied for 137 invention patents in different countries around the world, of which 71 patents have been granted, including 26 in China and 45 overseas. < / P > < p > it is worth noting that Zejing pharmaceutical is an innovative drug research and development institution, and there is a huge risk of failure in the research and development itself. Moreover, there is no drug on the market, and there are more innovative drugs under its control in the clinical trial research stage. < p > < p > Zejing pharmaceutical has done enough in the semi annual report, which indicates that the company is still in the stage of product research and development, and its R & D expenditure is relatively large. The company has not yet obtained commercial sales approval for drugs, nor has it obtained any drug sales income. Therefore, the company will not be able to make profits or make profit distribution in a certain period in the future. In other words, it is impossible to accurately judge the growth of Zejing pharmaceutical. If investors into a coax, it may take a long time to “run.”. < / P > < p > for example, China Securities construction investment recently proposed that Zejing pharmaceutical will have more catalytic events in the coming year, including: donafinil liver cancer first-line get priority review, colorectal cancer third-line clinical phase III data blinding and application for listing, double antibody and triple antibody of tumor immune biological drugs are expected to submit ind application; jacketinb is expected to complete phase II clinical, or it is possible to apply for listing under conditions. < / P > < p > the agency explained that at present, the first-line treatment options for advanced liver cancer were limited, and there were no more drugs with outstanding curative effect in the past long time. The clinical approval of zojing pharmaceutical sorafenib was of great clinical significance at that time. The number of patients with liver cancer in China is huge, and the market certainty is high. This clinical study of donafinil shows that sorafenib is effective and applied for listing, which indicates that the liver cancer treatment market is about to usher in a new therapeutic force. < / P > < p > according to the data, the number of shareholders of Zejing pharmaceutical was reduced from 36600 on January 23 to 12600 on June 30, fully disappearing 24000. < p > < p > as of June 30, a total of 19 public funds held Zejing pharmaceutical, with only half of the funds under active management, while the rest were passive index funds. The latter held a large amount of individual stocks and was more “Dragonfly”.